Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients

Abstract Background Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement of concentrations of active tamoxifen metabolites in serum may be a mo...

Full description

Bibliographic Details
Main Authors: Thomas Helland, Nina Henne, Ersilia Bifulco, Bjørn Naume, Elin Borgen, Vessela N. Kristensen, Jan T. Kvaløy, Timothy L. Lash, Grethe I. G. Alnæs, Ron H. van Schaik, Emiel A. M. Janssen, Steinar Hustad, Ernst A. Lien, Gunnar Mellgren, Håvard Søiland
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Breast Cancer Research
Subjects:
Tamoxifen
Adjuvant
Metabolism
Survival
CYP2D6
Endoxifen
Online Access:http://link.springer.com/article/10.1186/s13058-017-0916-4

Internet

http://link.springer.com/article/10.1186/s13058-017-0916-4

Similar Items